Blood cancers arise from genetic and epigenetic alterations in immune cell differentiation and activation, along with changes in the immune microenvironment. Understanding the mechanisms driving disease initiation, progression, immune escape, and therapeutic resistance is essential for improving patient outcomes and developing better biomarkers and treatments. Over the past decade, immunotherapy has transformed care for haematological malignancies: CAR-T cell therapies, bispecific T-cell engagers, checkpoint inhibitors, and NK-cell–based approaches are now reshaping clinical outcomes for diseases once associated with very poor prognoses. Yet critical questions remain about how tumour–immune interactions influence treatment response, resistance, and long-term disease control.

The IJC Symposium "Immunity in Haematological Malignancies: From Molecular Mechanisms to Transformative Therapies" will explore how fundamental immunological discoveries are being translated into next-generation treatments for leukaemia, lymphoma, and myeloma — from immune dysregulation and tumour evasion to CAR-T engineering, bispecific antibodies, and late-breaking clinical trial results.

Organisers: Biola M. Javierre, Esteban Ballestar and Tomas Navarro.

IJC Auditorium
Inscripción